Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Neurogene Inc (NGNE)

Neurogene Inc (NGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors Business Wire - Mon Apr 20, 6:30AM CDT

Ms. Shafer, a proven commercial leader in rare neurological diseases, will lead Neurogene’s commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome ...

NGNE : 27.03 (+0.30%)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Wed Apr 8, 3:01PM CDT

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 27.03 (+0.30%)
Neurogene: Q4 Earnings Snapshot AP - Tue Mar 24, 6:46AM CDT

Neurogene: Q4 Earnings Snapshot

NGNE : 27.03 (+0.30%)
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates Business Wire - Tue Mar 24, 6:30AM CDT

100% of participants enrolled in Embolden™ registrational trial and >50% of participants dosed; on track to complete dosing in second quarter of 2026 NGN-401 has been...

NGNE : 27.03 (+0.30%)
Neurogene to Participate in Stifel 2026 Virtual CNS Forum Business Wire - Wed Mar 11, 6:30AM CDT

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management...

NGNE : 27.03 (+0.30%)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Tue Mar 3, 3:01PM CST

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 27.03 (+0.30%)
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome Business Wire - Thu Feb 26, 3:01PM CST

Breakthrough Therapy designation granted based on interim NGN-401 Phase 1/2 data demonstrating clinically meaningful, durable and multidomain functional improvements On...

NGNE : 27.03 (+0.30%)
Neurogene to Participate in Upcoming Investor Conferences Business Wire - Thu Feb 5, 6:30AM CST

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management...

NGNE : 27.03 (+0.30%)
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Wed Feb 4, 3:01PM CST

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 27.03 (+0.30%)
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome Business Wire - Mon Jan 12, 6:00AM CST

Dosed multiple participants in Embolden™ registrational trial in fourth quarter of 2025 Completion of dosing in Embolden expected in second quarter of 2026 ...

NGNE : 27.03 (+0.30%)

Barchart Exclusives

Intel Could Still Be Undervalued Based on Strong Free Cash Flow Barchart - 2 minutes ago
Analysts are upgrading their Intel Corp price targets based on management's expectation of positive free cash flow this year. One way to play it is to sell short INTC out-of-the-money puts, with high yields. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.